Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUNGVAC study of anti-PD-1/PD-L1 therapy with or without UV1 vaccination in first-line advanced NSCLC
2021-005729-25Phase 2Active
- Sponsor
- Vestre Viken Hospital Trust
- Start
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of UV1, pembrolizumab and sargramostim in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Vestre Viken Hospital Trust. Primary endpoint: Progression-free survival. Started Nov 2021; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-005729-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005729-25.